-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: George Goodno
When it Comes to Patients, There is No Average
Next month, the National Pharmaceutical Council will host a forum — which BIO is cosponsoring — that will focus on the unique differences among treatment effects in individual patients and how policymakers, payers, and providers could shape programs and policies to acknowledge those differences. The forum, “The Myth of Average: Why Individual Patient Differences Matter” is taking place on November 30 at the Omni Shoreham Hotel in Washington, D.C. More information and registration materials are available Read More >
Biotech is Growing in Colorado
Last month I posted a link to an interview featuring Colorado BioScience Association‘s (CBSA) Executive Vice President, April Giles. The interview briefly touched on some of the innovation happening in the state. Though, I was curious to know a bit more about CBSA’s effort to grow and support the industry. So, I was pleased when April kindly agreed to participate in a Q&A. Her answers below offer insight into critical elements of bioscience economic development Read More >
eAdvocacy Summit Brings Together More Than 130 Groups
BIO’s mission is to champion biotechnology issues by advocating for policies that will enable the realization of breakthrough products to cure disease, feed the hungry, and clean our environment. Fortunately, we are not alone – our many alliance and advocacy partners share our goal. When smart, like-minded people get together, good things tend to happen. That’s why I’m looking forward to tomorrow’s eAdvocacy Summit here in Washington, DC. The Global Healthy Living Foundation (GHLF) and Read More >
BayBio Op-ed featured in Xconomy
Gail Maderis, President & CEO of BayBio, recently discussed the strength of Northern California’s biotechnology industry and the BIO Investor Forum in Xconomy: With more than 850 biotechnology companies, the Bay Area is the oldest, largest and most productive life sciences cluster in the world, employing more than 125,000 people in the region. For more than 30 years, this region has led the world in researching and delivering new cures and treatments for debilitating diseases Read More >
Southern California Biotech Magnet School will Prepare Next Gen Workforce
Despite increasing global competition, the United States remains the most innovative country on the planet. This competition, of course, is good because it means education and research are growing in the rest of the world. There is some debate as to whether or not this nation is facing a potential hi-tech labor shortage. Though, one thing is certain – teaching science, math, and technology to all kids is so important. This is not just because Read More >




